PL390683A1 - Zastosowanie pochodnych pirolu do wytwarzania leku - Google Patents

Zastosowanie pochodnych pirolu do wytwarzania leku

Info

Publication number: PL390683A1
Authority: PL; Poland
Prior art keywords: compound; pyrrole derivatives; drug manufacturing; isoindolinone; prodrug
Prior art date: 2001-04-30

Application number

PL39068302A

Other languages

English (en)

Other versions

PL207725B1 (pl

Inventor

Cathryn Montgomery Clary

Beek Jeroen Bernard Van

Perry Steven Eisman

Sean David Donevan

Atul Chandra Pande

Richard James Kavoussi

Lyou-Fu Ma

Original Assignee

Endo Pharmaceuticals Solutions

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-30

Filing date

2002-04-29

Publication date

2010-05-24

2002-04-29 Application filed by Endo Pharmaceuticals Solutions filed Critical Endo Pharmaceuticals Solutions

2010-05-24 Publication of PL390683A1 publication Critical patent/PL390683A1/pl

2011-01-31 Publication of PL207725B1 publication Critical patent/PL207725B1/pl

Links

238000007905 drug manufacturing Methods 0.000 title 1
150000003233 pyrroles Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
230000003287 optical effect Effects 0.000 abstract 2
229940002612 prodrug Drugs 0.000 abstract 2
239000000651 prodrug Substances 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
ADHYPRBHQVZOTP-UHFFFAOYSA-N 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-hydroxy-5-methyl-2-oxohexyl)-3h-isoindol-1-one Chemical compound C1=CC(Cl)=NC2=NC(N3C(C4=CC=CC=C4C3=O)CC(=O)CCC(C)(O)C)=CC=C21 ADHYPRBHQVZOTP-UHFFFAOYSA-N 0.000 abstract 1
206010041250 Social phobia Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
HIUPRQPBWVEQJJ-UHFFFAOYSA-N pagoclone Chemical compound C1=CC(Cl)=NC2=NC(N3C(C4=CC=CC=C4C3=O)CC(=O)CCC(C)C)=CC=C21 HIUPRQPBWVEQJJ-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL390683A 2001-04-30 2002-04-29 Zastosowanie pochodnych pirolu do wytwarzania leku PL207725B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US28754501P	2001-04-30	2001-04-30

Publications (2)

Publication Number	Publication Date
PL390683A1 true PL390683A1 (pl)	2010-05-24
PL207725B1 PL207725B1 (pl)	2011-01-31

Family

ID=23103396

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL390683A PL207725B1 (pl)	2001-04-30	2002-04-29	Zastosowanie pochodnych pirolu do wytwarzania leku
PL353681A PL207738B1 (pl)	2001-04-30	2002-04-29	Zastosowanie 2-(7-chloro-1,8-naftyrydyn-2-ylo)-3-(5-metylo-2-oksoheksylo)-1-izoindolinonu lub 2-(7-chloro-1,8-naftyrydyn-2-ylo)-3- (5-metylo-5-hydroksy-2-oksoheksylo)-1-izoindolinonu albo ich farmaceutycznie dopuszczalnej soli lub izomeru optycznego do wytwarzania leku

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL353681A PL207738B1 (pl)	2001-04-30	2002-04-29	Zastosowanie 2-(7-chloro-1,8-naftyrydyn-2-ylo)-3-(5-metylo-2-oksoheksylo)-1-izoindolinonu lub 2-(7-chloro-1,8-naftyrydyn-2-ylo)-3- (5-metylo-5-hydroksy-2-oksoheksylo)-1-izoindolinonu albo ich farmaceutycznie dopuszczalnej soli lub izomeru optycznego do wytwarzania leku

Country Status (20)

Country	Link
US (2)	US7026332B2 (pl)
EP (2)	EP1642576B1 (pl)
JP (1)	JP2002326934A (pl)
KR (1)	KR20020084413A (pl)
CN (1)	CN1384104A (pl)
AT (2)	ATE331513T1 (pl)
AU (1)	AU783516B2 (pl)
CA (1)	CA2383599C (pl)
CY (1)	CY1109129T1 (pl)
DE (2)	DE60231568D1 (pl)
DK (1)	DK1642576T3 (pl)
ES (2)	ES2267943T3 (pl)
HU (1)	HU228826B1 (pl)
IL (2)	IL149280A0 (pl)
MY (1)	MY129575A (pl)
NZ (1)	NZ518615A (pl)
PL (2)	PL207725B1 (pl)
PT (1)	PT1642576E (pl)
TW (1)	TWI302455B (pl)
ZA (1)	ZA200203347B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2007502856A (ja) *	2003-05-16	2007-02-15	ファイザー・プロダクツ・インク	精神病性障害および抑うつ性障害の治療
CA2525868A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Anxiety treatments with ziprasidone
DE602004024317D1 (de) *	2003-09-12	2010-01-07	Pfizer	Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
KR20060087560A (ko) *	2003-09-12	2006-08-02	워너-램버트 캄파니 엘엘씨	알파-2-델타 리간드 및 ｓｓｒｉ 및/또는 ｓｎｒｉ를포함하는 우울증 및 불안 장애 치료용 조합물
US20050232983A1 (en) *	2004-04-14	2005-10-20	Indevus Pharmaceuticals, Inc.	Transdermal patch
WO2005107719A2 (en) *	2004-05-06	2005-11-17	Sandoz Ag	Pharmaceutical composition comprising hydrophobic drug having improved solubility
SG176464A1 (en)	2008-05-09	2011-12-29	Agency Science Tech & Res	Diagnosis and treatment of kawasaki disease
EP2678337A1 (en) *	2011-02-25	2014-01-01	Concert Pharmaceuticals Inc.	2-amino-naphthyridine derivatives
SG11202109526PA (en) *	2019-03-18	2021-10-28	Neurocycle Therapeutics Inc	Use of gabaa receptor modulators for treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2607503B1 (fr)	1986-12-02	1989-02-24	Rhone Poulenc Sante	Nouveaux derives de l'isoindolinone, leur preparation et les compositions pharmaceutiques qui les contiennent
DE3814022A1 (de) *	1988-04-26	1989-11-09	Davy Mckee Ag	Verfahren zur herstellung linearer polyester, insbesondere fuer filme und folien
EP0521622B1 (en)	1991-07-03	1997-08-13	PHARMACIA & UPJOHN COMPANY	Pyrazolopyrimidine and pyrimidinyl bisphosphonic esters as anti-inflammatories
FR2678934B1 (fr)	1991-07-12	1995-01-13	Rhone Poulenc Rorer Sa	Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2678932B1 (fr)	1991-07-12	1993-09-24	Rhone Poulenc Rorer Sa	Procede de preparation des isomeres optiques d'un derive de l'amino-2 naphtyridine.
FR2681068B1 (fr)	1991-09-09	1993-11-19	Rhone Poulenc Rorer Sa	Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone.
FR2684673B1 (fr)	1991-12-04	1994-01-21	Rhone Poulenc Rorer Sa	Procede de preparation d'un derive de l'amino-2 naphtyridine racemique.
FR2687154B1 (fr) *	1992-02-07	1995-05-12	Rhone Poulenc Rorer Sa	Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
FR2695389B1 (fr)	1992-09-08	1994-11-04	Rhone Poulenc Rorer Sa	Nouveau dérivé de l'isoindolinone, sa préparation et les compositions pharmaceutiques qui le contiennent.
US5498716A (en) *	1994-01-12	1996-03-12	Rhone-Poulenc Rorer S.A.	2-amino naphthyridine derivative, its preparation and its use
GB2305859A (en) *	1996-03-29	1997-04-23	Lilly Co Eli	Treatment of obsessive-compulsive disorder
US6541669B1 (en) *	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
WO2001008670A2 (en) *	1999-07-29	2001-02-08	Interneuron Pharmaceuticals, Inc.	Methods and compositions for alleviating stuttering
DE19939980A1 (de)	1999-08-24	2001-03-01	Merck Patent Gmbh	Inhibitoren des Integrins alphavbeta¶3¶
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function

2002
- 2002-03-22 AU AU27609/02A patent/AU783516B2/en not_active Ceased
- 2002-03-28 MY MYPI20021125A patent/MY129575A/en unknown
- 2002-04-16 ES ES02252684T patent/ES2267943T3/es not_active Expired - Lifetime
- 2002-04-16 AT AT02252684T patent/ATE331513T1/de not_active IP Right Cessation
- 2002-04-16 EP EP05028364A patent/EP1642576B1/en not_active Expired - Lifetime
- 2002-04-16 EP EP02252684A patent/EP1254660B1/en not_active Expired - Lifetime
- 2002-04-16 DE DE60231568T patent/DE60231568D1/de not_active Expired - Lifetime
- 2002-04-16 DE DE60212757T patent/DE60212757T2/de not_active Expired - Lifetime
- 2002-04-16 AT AT05028364T patent/ATE424820T1/de active
- 2002-04-16 PT PT05028364T patent/PT1642576E/pt unknown
- 2002-04-16 ES ES05028364T patent/ES2323646T3/es not_active Expired - Lifetime
- 2002-04-16 DK DK05028364T patent/DK1642576T3/da active
- 2002-04-18 CN CN02116105A patent/CN1384104A/zh active Pending
- 2002-04-22 IL IL14928002A patent/IL149280A0/xx not_active IP Right Cessation
- 2002-04-22 IL IL204665A patent/IL204665A/en not_active IP Right Cessation
- 2002-04-25 US US10/133,471 patent/US7026332B2/en not_active Expired - Fee Related
- 2002-04-25 JP JP2002123928A patent/JP2002326934A/ja active Pending
- 2002-04-26 ZA ZA2002/03347A patent/ZA200203347B/en unknown
- 2002-04-26 CA CA002383599A patent/CA2383599C/en not_active Expired - Fee Related
- 2002-04-29 TW TW091108876A patent/TWI302455B/zh not_active IP Right Cessation
- 2002-04-29 HU HU0201394A patent/HU228826B1/hu not_active IP Right Cessation
- 2002-04-29 NZ NZ518615A patent/NZ518615A/en not_active IP Right Cessation
- 2002-04-29 PL PL390683A patent/PL207725B1/pl unknown
- 2002-04-29 KR KR1020020023430A patent/KR20020084413A/ko not_active Ceased
- 2002-04-29 PL PL353681A patent/PL207738B1/pl unknown
2006
- 2006-02-13 US US11/352,286 patent/US7553847B2/en not_active Expired - Fee Related
2009
- 2009-06-01 CY CY20091100582T patent/CY1109129T1/el unknown

Also Published As

Publication number	Publication date
JP2002326934A (ja)	2002-11-15
CA2383599A1 (en)	2002-10-30
TWI302455B (en)	2008-11-01
DE60231568D1 (de)	2009-04-23
ES2267943T3 (es)	2007-03-16
MY129575A (en)	2007-04-30
PL353681A1 (en)	2002-11-04
DK1642576T3 (da)	2009-04-14
DE60212757D1 (de)	2006-08-10
ATE424820T1 (de)	2009-03-15
ES2323646T3 (es)	2009-07-22
HK1094307A1 (en)	2007-03-30
IL204665A (en)	2011-05-31
PL207725B1 (pl)	2011-01-31
CN1384104A (zh)	2002-12-11
AU2760902A (en)	2002-10-31
EP1254660A2 (en)	2002-11-06
US7553847B2 (en)	2009-06-30
PT1642576E (pt)	2009-05-21
EP1254660A3 (en)	2003-03-26
DE60212757T2 (de)	2007-06-28
EP1254660B1 (en)	2006-06-28
US20030022915A1 (en)	2003-01-30
EP1642576A2 (en)	2006-04-05
PL207738B1 (pl)	2011-01-31
US7026332B2 (en)	2006-04-11
US20060128746A1 (en)	2006-06-15
HUP0201394A2 (hu)	2002-12-28
EP1642576A3 (en)	2007-01-10
HUP0201394A3 (en)	2003-12-29
EP1642576B1 (en)	2009-03-11
AU783516B2 (en)	2005-11-03
ATE331513T1 (de)	2006-07-15
NZ518615A (en)	2004-03-26
CA2383599C (en)	2006-10-31
ZA200203347B (en)	2003-11-26
HU0201394D0 (pl)	2002-06-29
IL149280A0 (en)	2002-11-10
KR20020084413A (ko)	2002-11-07
HU228826B1 (en)	2013-05-28
CY1109129T1 (el)	2014-07-02

Publication	Publication Date	Title
HUS2100028I1 (hu)	2021-08-30	ERBB I. típusú receptor tirozinkináz-gátló N4-fenil-kinazolin-4-amin származékok és rokon vegyületeik a hiperproliferatív betegségek kezelésére
ATE440603T1 (de)	2009-09-15	8-hydroxychinolinderivate
WO2006110816A3 (en)	2007-01-04	1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
WO2002057252A3 (en)	2002-12-12	Heterocyclic sulfonamide inhibitors of beta amyloid production
WO2001019829A3 (en)	2001-09-27	Pyrazolopyrimidines as therapeutic agents
NO20060408L (no)	2006-04-04	Fremgangsmate for a modulere kalsium ione-frigjorings- aktivert kalsium ionekanaler
UA93351C2 (uk)	2011-02-10	Похідні фталазіну як інгібітори parp
EA200401160A1 (ru)	2005-02-24	Производные тиазола и оксазола, которые модулируют активность ppar
ATE522509T1 (de)	2011-09-15	Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
DK1578740T3 (da)	2007-07-30	1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet
DK2054418T3 (da)	2012-02-27	Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
MXPA04006184A (es)	2004-12-06	Compuestos derivados de 1h-pirazolilo, para el uso en enfermedades asociadas con el receptor 5-ht2c.
EA200801308A1 (ru)	2009-02-27	Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик
ATE277072T1 (de)	2004-10-15	Sapogenin derivate zur behandlung von kognitiven störungen
CY1109129T1 (el)	2014-07-02	Χρηση παραγωγων πυρρολιου για καταπολεμηση του αγχους
NO20034123L (no)	2003-09-16	Fremgangsmåte for behandling av brennstoff
WO2003057213A3 (en)	2004-02-19	Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor
ATE407923T1 (de)	2008-09-15	Tyrosinderivate als phosphatase inhibitoren
DE602005007765D1 (de)	2008-08-07	Neue indol- oder benzimidazol-derivate
DE60142304D1 (de)	2010-07-15	Substituierte heterocyclische verbindungen und deren verwendung zur behandlung multipler medikamentenresistenz
AU2002364711A1 (en)	2003-06-30	Substituted 5-hydroxy-indole compounds for the treatment of glaucoma
DK1553938T3 (da)	2007-03-26	Anvendelse af epothilonderivater til behandling af hyperparathyroidisme
ZA200400824B (en)	2004-07-20	Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.